ACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS.
|
|
- Rodger Fitzgerald
- 5 years ago
- Views:
Transcription
1 ACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS. ÁLVARO PINTO Servicio de Oncología Médica Hospital Universitario La Paz IdiPAZ, Madrid
2 INTRODUCTION High prevalence of bone metastases in the setting of mcrpc Associated with morbidity and mortality Skeletal related events (SREs) - Spinal cord compression (SCC) - Pathologic fracture - Need for surgery - Palliative radiotherapy Influence in survival and quality of life Economic burden 5 10% lymph node only ~20% bone visceral disease < 5% visceral only ~70 % bone lymph nodes
3 INTRODUCTION Patients With SRE, % Any Pathologic fracture Radiation therapy Surgical intervention Spinal cord compression 24 months Saad F, et al. JNCI. 2002;94(19): ; Saad F, et al. Eur Urol Suppl. 2007;6(11):
4 INTRODUCTION Probability No SRE (n = 355) 1 SRE (n = 116) Survival, days 360 Days Survival No SRE: 49.7% 1 SRE: 28.2% P =.02 Median Survival Times No SRE: 338 days (95% CI = 189, 460) 1 SRE: 248 days (95% CI = 181, 296) SREs Are Associated With Lower Survival in Prostate Cancer DePuy V, et al. Support Care Cancer. 2007;15:
5 INTRODUCTION Total Physical Functional Emotional Change/Standard Deviation a a a a a a Change in FACT-G score for patients with an event vs patients without an event a P <.05. Weinfurt et al. Ann Oncol. 2005;16(4):
6 INTRODUCTION Median average cost: $ Inpatient SREs: $ Outpatient SREs: $ Hospital stay: range 1-65 days SCC: 11.5 days Radiaton to bone: Surgery to bone: Pathologic fracture: SCC: Average hospital length of stay: 21.6 days (75% of all costs) Yong et al. Curr Opin Oncol 2014;26:274-83; Durán et al. Clin Transl Oncol 2014;16:322-9.
7 BONE TARGETED THERAPY DOES IT MAKE SENSE?
8 Deng et al. Cancer Treat Rev 2014;40:730-8
9 DENOSUMAB
10 DENOSUMAB Key Inclusion Criteria Castration-resistant prostate cancer and 1 bone metastases Key Exclusion Criteria Current or prior IV bisphosphonate treatment R A N D O M I Z A T I O N Denosumab 120 mg SC and Placebo IV* every 4 weeks (n=950) Zoledronic Acid 4 mg IV* and Placebo SC every 4 weeks (n=951) E N D O F S T U D Y Recommended: Daily supplementation with calcium ( 500 mg) and vitamin D ( 400 U) Primary Endpoint: Time to first on-study skeletal-related event (SRE) (Non-inferiority) Secondary : Time to first on-study SRE (Superiority), time to first and subsequent on-study SRE(s) (Superiority) Fizazi et al. Lancet 2011;377:813-22
11 DENOSUMAB Fizazi et al. Lancet 2011;377:813-22
12 DENOSUMAB Fizazi et al. Lancet 2011;377:813-22
13 DENOSUMAB ADVERSE EVENTS Fizazi et al. Lancet 2011;377:813-22
14 DENOSUMAB - HYPOCALCEMIA CONDITION RECOMMENDED STRATEGY Pre existing hypocalcemia Treat before initiating therapy Start of treatment Together with at least 500 mg of calcium and 400 UI of vitamin D daily Severe renal failure (creatinine clearance < 30 ml/min) or undergoing dialysis Monitor calcium levels Hypocalcemia during therapy Consider additional calcium supplementation
15 DENOSUMAB SEVERE RENAL FAILURE (ESMO 2014) S C R E E N I N G Informed consent Screening assessments Begin/adjust calcium and vitamin D supplementation (stage 4 CKD patients) Stage 4 CKD (CrCl <30 ml/min) (n=15) Denosumab 120 mg SC Stage 5D CKD, requiring hemodialysis (n=15) Denosumab 120 mg SC Dose 1 Dose 2 E N D O F S T U D Y Clinically significant adverse events or laboratory abnormalities were followed until resolution/considered stable Days -21 to Day -1 Day 1 Day 29 Day 112 Day 113 PRIMARY OBJECTIVE: Incidence of clinically significant hypocalcemia Block et al. ESMO 2014: abstract 1512P and poster presentation.
16 DENOSUMAB SEVERE RENAL FAILURE (ESMO 2014) CKD Patients, n (%) Stage 4 (n=16) Stage 5D (n=16) All (n=32) Albumin adjusted serum calcium <7.0 mg/dl * 0 (0.0) 1 (6.3) 1 (3.1) Symptomatic hypocalcemia 1 (6.3) 1 (6.3) 2 (6.3) Total: clinically significant hypocalcemia 1 (6.3) 2 (12.5) 3 (9.4) *CTCAE grade 3 or greater hypocalcemia (<7.0 mg/dl [1.75 mmol/l]); Defined as both a clinical adverse event of hypocalcemia and a concomitant symptom of hypocalcemia (e.g., hypoesthesia, paresthesia, muscle cramps, seizure, prolonged QT interval) that occurred along with the hypocalcemia event or decreased serum calcium levels; Defined as albumin adjusted calcium <7.0 mg/dl (1.75 mmol/l) or symptomatic hypocalcemia Block et al. ESMO 2014: abstract 1512P and poster presentation.
17 DENOSUMAB OSTEONECROSIS OF THE JAW Prostate cancer Overall ONJ events* 0 12 Months Pt years Pts at beginning of time period, n Pts with ONJ events, n (rate) > 12 Months Pt years Pts at beginning of time period, n Pts with ONJ events, n (rate) Total Pt years Pts at beginning of time period, n Pts with ONJ events, n (rate) ZA (n = 945) (0.7) (2.0) (1.2) Dmab (n = 943) (1.4) (3.4) (2.1) ZA (n = 2836) (0.8) (2.2) (1.3) Dmab (n = 2841) (1.0) (3.3) (1.9) P value Lipton et al. ASCO 2013 [abstract #9640]
18 DENOSUMAB PAIN CONTROL
19 OSTEOCLAST-TARGETED AGENTS Gartrell et al. Nat Rev Clin Oncol 2014;11:335-45
20 DENOSUMAB - CONCLUSIONS Active agent to prevent delay the onset of SREs Superiority over zoledronic acid No impact on survival Advantages over zoledronic acid: Subcutaneous administration No need of normal renal function Watch out for osteonecrosis of the jaw and hypocalcemia
21 RADIUM-223 Alkaline earth metal Bone seeker (calcium mimic) α-emitter, 28 MeV t ½ = 11.4 days High linear energy transfer Track length < 100 μm 2 10 cell diameter impact Strong cell killing effect 20 Ca Sr Ba Ra 88 McDevitt MR, et al. Eur J Nucl Med. 1998;25(9):
22 RADIUM-223 α β γ α radiation consists of helium ( 4 He) nuclei and is stopped by a sheet of paper or skin β radiation, consisting of electrons, is halted by an aluminum plate or plastic Paper Aluminum Lead or concrete Water or polyethylene γ radiation, consisting of energetic photons, is attenuated by dense material
23 RADIUM-223 ALSYMPCA TRIAL TREATMENT PATIENTS Confirmed symptomatic CRPC 2 bone metastases No known visceral metastases Postdocetaxel or unfit for docetaxel STRATIFICATION Total ALP: < 220 U/L vs 220 U/L Bisphosphonate use: Yes vs No Prior docetaxel: Yes vs No R A N D O M I S E D 2:1 N = injections at 4-week intervals Radium-223 (50 kbq/kg) + Best standard of care Placebo (saline) + Best standard of care PRIMARY ENDPOINT: OVERALL SURVIVAL
24 RADIUM-223 Patients With Adverse Events (AEs), n (%) Radium-223 (n = 509) Placebo (n = 253) All grade AEs 450 (88) 237 (94) Grade 3 or 4 AEs 257 (51) 150 (59) Serious AEs (SAEs) 220 (43) 139 (55) Discontinuation due to AEs 68 (13) 51 (20) Parker et al. NEJM 2013;369:213-23
25 RADIUM-223 SYMPTOMATIC SKELETAL EVENTS Sartor et al. Lancet Oncol 2014;15:738-46
26 RADIUM-223 SYMPTOMATIC SKELETAL EVENTS Sartor et al. Lancet Oncol 2014;15:738-46
27 RADIUM-223 PREVIOUS DOCETAXEL Improvement in OS irrespective of previous docetaxel Previous docetaxel: HR 0.70 (p=0.002) No previous docetaxel: HR 0.69 (p=0.01) Higher incidence of grade 3-4 thrombocytopenia in previously treated with docetaxel (9% vs 3%) No differences in grade 3-4 anemia or neutropenia Hoskin et al. Lancet Oncol 2014;15:
28 RADIUM CONCLUSIONS Radiopharmaceutical that prolongs overall survival Delay in the occurrence of SREs Good safety profile Potential for combination strategies For symptomatic mcrpc patients, without visceral disease Post-docetaxel or non-candidates ( unfit ) for docetaxel
29 BONE TARGETED THERAPY ANYTHING ELSE?
30 CABOZANTINIB Dual blockade of Met and VEGFR-2 Role of Met/HGF in osteoblast/osteoclast activity Prostate cancer: Impressive bone responses Difficult safety profile Pinto A. Cancer Chemother Pharmacol 2014;73:219-22
31 CABOZANTINIB PHASE II Smith et al. J Clin Oncol 2013;31:412-9
32 CABOZANTINIB PHASE III COMET TRIALS COMET-1 failed its primary endpoint (OS) 11.0 vs 9.8 months (HR 0.9, p=0.212) PFS: 5.5 vs 2.8 months (HR 0.5, p<0.0001) COMET-2 has been deprioritized by the company
33 TRAPEZE TRIAL (CRPC WITH BONE METASTASIS) A Docetaxel 75 mg/m 2 Q3W + prednisolone 10 mg OD (Cycles 1 10) B Docetaxel + prednisolone + zoledronic acid 4 mg IV (Cycles 1 10) C Docetaxel + prednisolone (Cycles 1 6) Sr MBq (Day 28 Cycle 6) 28 days Docetaxel + prednisolone (Cycles 7 10) D Docetaxel + prednisolone + zoledronic acid (Cycles 1 6) Sr89 MBq (Day 28 Cycle 6) 28 days Docetaxel + prednisolone + zoledronic acid (Cycles 7 10) James N, et al. ASCO 2013 [Abstract #LBA5000].
34 TRAPEZE TRIAL (CRPC WITH BONE METASTASIS) Composite primary outcomes: Bony clinical progression-free survival (CPFS) defined as the first occurrence of: Clinical SRE (no blinded radiological assessment) Death from any cause Bone pain progression Key secondary outcomes: SRE-free interval and total SREs Overall survival James N, et al. ASCO 2013 [Abstract #LBA5000].
35 TRAPEZE TRIAL PRIMARY OBJECTIVE Outcome Sr89 comparison Zoledronic acid comparison No Sr89 Sr89 No ZA ZA CPFS, n Median, months Univariable HR (95% CI) P value Multivariable HR (95% CI) P value 0.84 ( ) P = ( ) P = ( ) P = P = 0.46 James N, et al. ASCO 2013 [Abstract #LBA5000].
36 TRAPEZE TRIAL SECONDARY OBJECTIVES Outcome Sr89 comparison Zoledronic acid comparison No Sr89 Sr89 No ZA ZA SRE free interval, n Median, months Univariable HR (95% CI) P value 0.91 ( ) P = ( ) P = Overall survival HR (95% CI) P value ( ) P = ( ) P = James N, et al. ASCO 2013 [Abstract #LBA5000].
37 TRAPEZE TRIAL - CONCLUSIONS Sr89 but not zoledronic acid increased bony CPFS (multivariable analysis) Small increase of 1 month, clinically relevant? Zoledronic acid but not Sr89 increased SRE-free interval and decreased total SREs Mostly post-progression No significant differences in toxicity between arms Neither agent had any impact on overall survival
38 PATIENT PREFERENCE Patients from United Kingdom (n=201) and Sweden (n=200) Nearly 80% would trade off at least 3 months of survival to avoid SREs More than 80% would accept a risk of ONJ up to 9% (the highest tested one)
39 COMBINATIONS ERA223 TRIAL N=800 mcrpc patients: Asymptomatic or minimally symptomatic No prior CT No visceral disease R A N D O M I Z E ABIRATERONE 1000 mg daily PREDNISONE 5 mg BID PLACEBO ABIRATERONE 1000 mg daily PREDNISONE 5 mg BID RADIUM kbq/kg every 4wk PRIMARY OBJECTIVE: Symptomatic skeletal event free survival Secondary objectives: OS, rpfs, time to pain progression, time to opiate use, time to chemotherapy, safety, QoL
40 COMBINATIONS PEACE-III TRIAL N=560 mcrpc patients: Asymptomatic or minimally symptomatic No visceral disease Previous CHAARTED allowed R A N D O M I Z E ENZALUTAMIDE 160 mg daily PLACEBO ENZALUTAMIDE 160 mg daily RADIUM kbq/kg every 4wk PRIMARY OBJECTIVE: rpfs Secondary objectives: OS, first symptomatic skeletal event, time to pain progression, time to opiate use, safety, QoL
41 COMBINATIONS DOCETAXEL (phase I/IIa) N=60 mcrpc patients with 2 bone mets R A N D O M I Z E 2:1 Radium 223 dichloride 50 kbq/kg q6w + Docetaxel 60 mg/m 2 q3w Docetaxel 75 mg/m 2 q3w PRIMARY OBJECTIVE: Dose-limiting toxicities, safety Secondary objectives: exploratory efficacy measurements (PSA response, ALP response, CTCs), patient self-reports about pain intensity
42 COMBINATIONS DOCETAXEL (phase I/IIa) ESMO-2014 (Morris et al) 2 cases of febrile neutropenia (both had D alone) 1 case of anemia G3-4 (Ra+D), 2 with G1 (both D) No thrombocytopenia More patients completed Ra+D vs D alone Expanded safety cohort continues as panned Morris et al. ESMO 2014 [Poster presentation]
43 RADIUM-223 ALTERNATIVE SCHEDULES N=360 mcrpc patients: 2 bone metastasis No visceral disease R A N D O M I Z E Radium 223 dichloride 50 kbq/kg q4w x 6 cycles Radium 223 dichloride 50 kbq/kg q4w x 12 cycles Radium 223 dichloride 80 kbq/kg q4w x 6 cycles PRIMARY OBJECTIVE: Symptomatic skeletal event free survival Secondary objectives: OS, rpfs, time to pain progression, pain improvement rate, safety
44 RADIUM-223 RE-TREATMENT (phase I-II) N=40 mcrpc patients: Previous therapy with 6 doses of Ra 223 No SAE or grade 3 4 toxicity with Ra 223 No visceral disease Radium 223 dichloride 50 kbq/kg q4w x 6 cycles PRIMARY OBJECTIVE: Safety Secondary objectives: OS, rpfs, time to pain progression, pain improvement rate, time to first symptomatic skeletal event
45
46 CONCLUSIONS BONE TARGETED THERAPY AS A CORNERSTONE OF PROSTATE CANCER SREs QoL SURVIVAL PAIN SAFETY ROLE OF COMBINATIONS WITH OTHER ACTIVE AGENTS
47 THANK YOU FOR YOUR ATTENTION ÁLVARO PINTO Servicio de Oncología Médica Hospital Universitario La Paz IdiPAZ, Madrid
Bone-targeted therapies for prostate cancer in Institut Gustave Roussy Villejuif, France
Bone-targeted therapies for prostate cancer in 2012 Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards or speaker for: Amgen, Astellas-Medivation,
More informationBone targeting: bisphosphonates, RANK-ligands and radioisotopes. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Bone targeting: bisphosphonates, RANK-ligands and radioisotopes Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee
More informationIndex Patients 3& 4. Guideline Statements 10/11/2014. Enzalutamide Reduced the Risk of Death
//4 Prolonged Radiographic Progression-Free Survival Reduced the Risk of Death Overall ITT Population Estimated median rpfs, months (9% CI): : NYR (.8 NYR); placebo:.9 (.7.4) rpfs (%) ( Enza 9 8 7 4 8
More informationIsotopes and Palliative Radiotherapy for bone metastases
Isotopes and Palliative Radiotherapy for bone metastases Rationale for Bone-seeking Isotope Therapies in Prostate Cancer > 90% of patients with advanced prostate cancer have bone metastases which can be
More informationCastrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Castrate-resistant prostate cancer: Bone-targeted agents Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for: Amgen, Astellas,
More informationIsotopes and Palliative Radiotherapy for bone metastases
Isotopes and Palliative Radiotherapy for bone metastases Rationale for Bone-seeking Isotope Therapies in Prostate Cancer > 90% of patients with advanced prostate cancer have bone metastases which can be
More informationElderly men with prostate cancer + ADT
Elderly men with prostate cancer + ADT Background and Rationale ADT and Osteoporosis Proportion of Patients With Fractures 1-5 Yrs After Cancer Diagnosis 21 18 +6.8%; P
More informationSYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223
SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 4-5 October 2018 Disclosures Participation in advisory boards:
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer SAMO Masterclass 4 th March 2016 Aurelius Omlin Conflicts of interest Advisory Rolle: Astra Zeneca, Astellas, Bayer, Janssen, Pfizer, Sanofi Aventis Research support: TEVA, Janssen
More informationUntil 2004, CRPC was consistently a rapidly lethal disease.
Until 2004, CRPC was consistently a rapidly lethal disease. the entry in systemic disease is declared on a an isolated PSA recurrence after local treatment so!!! The management of CRPC and MCRPC is different
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support
More informationAlpha-emitting Radionuclides: Ra-223
Alpha-emitting Radionuclides: Ra-223 prof. dr. K. Goffin Nuclear Medicine and Molecular Imaging Department of Imaging & Pathology UZ Leuven KU Leuven Belgium International Course on Theranostics and Molecular
More informationSESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia
SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract
More informationMÉTASTASES OSSEUSES ET RADIUM 223
MÉTASTASES OSSEUSES ET RADIUM 223 Marie-Laure Amram Service d oncologie Hôpitaux Universitaires de Genève Forome du 21.05.2015 Radium-22:3:mécanisme d action Mécanisme d action Mécanisme d action Radium-223
More informationRoberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena
Il Trattamento della Malattia CRPC metastatica Terapie Radiometaboliche Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena AIOM: Gestione ottimale del Paziente con Carcinoma della
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationASCO 2012 Genitourinary tumors
ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase
More informationΛουκάς Κοντοβίνης, παθολόγος - ογκολόγος.
Λουκάς Κοντοβίνης, παθολόγος - ογκολόγος l.kontovinis@oncomedicare.com Nuclear Medicine Review 2011, 14, 2: 96 104 N Engl J Med 2004;350:1655-64 Nuclear Medicine Review 2011, 14, 2: 96 104 N Engl J Med
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationPLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE. Daan De Maeseneer, Medisch Oncoloog
PLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE Daan De Maeseneer, Medisch Oncoloog 1 Overview DEAT PSA/Tumor Burden METASTASES INITIAL DIAGNOSIS & THERAPY ADT CRP SREs/
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationManagement of castration resistant prostate cancer after first line hormonal therapy fails
Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More information8/31/ ) Intermittent androgen deprivation in androgen-sensitive PCa. 1) Alpharadin (Ra223) in CRPC with bone metastases
Bruce J. Roth, M.D. Clinical Trials: Medivation, Oncogenix 1) Alpharadin (Ra223) in CRPC with bone metastases 2) Enzalutamide (MDV-31) in CRPC and prior docetaxel 3) Abiraterone in chemo-naïve CRPC 4)
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer January 13, 2017 Sindu Kanjeekal MD FRCPC Medical Oncology and Hematology Regional Systemic Quality Lead Erie St Clair Adjunct Professor Schulich School of Medicine and University
More informationProstate cancer update: Dr Robert Huddart Cancer Clinic London
Prostate cancer update: 2013 Dr Robert Huddart Cancer Clinic London Recent developments Improved imaging New radiotherapy technologies Radiotherapy for advanced disease Intermittent hormone therapy New
More informationIncorporating New Agents into the Treatment Paradigm for Prostate Cancer
Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center
More informationCurrent role of chemotherapy in hormone-naïve patients Elena Castro
Current role of chemotherapy in hormone-naïve patients Elena Castro Spanish National Cancer Research Centre Lugano, 17 October 2017 Siegel, Ca Cancer J Clin,2017 Buzzoni, Eur Urol, 2015 -Aprox 15-20% of
More informationAdvanced Prostate Cancer. SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin
Advanced Prostate Cancer SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin aurelius.omlin@kssg.ch Conflicts of Interest Research Support: TEVA, Janssen Advisory Rolle: Astra Zeneca, Astellas,
More informationPerspective on endocrine and chemotherapy agents. Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr. Sternberg has received research funding for
More informationEarly Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
More informationmcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE
mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE IL CARCINOMA PROSTATICO, UNA MALATTIA ETEROGENEA? RAZIONALE E RISULTATI DEL TRATTAMENTO CHEMIOTERAPICO ASSOCIATO ALL
More informationCancer de la prostate métastatique: prise en charge précoce
Cancer de la prostate métastatique: prise en charge précoce Stéphane Oudard, MD, PhD Georges Pompidou Hospital, Oncology Department, Paris, France stephane.oudard@egp.aphp.fr SAGB.CAB.14.08.0382c 3/02/2016
More informationCurrent Management of Metastatic Bone Disease
Current Management of Metastatic Bone Disease Evaluation and Medical Management Dr. Sara Rask Head, Medical Oncology Simcoe Muskoka Regional Cancer Centre www.rvh.on.ca Objectives 1. Outline an initial
More informationWhat will change for men with advanced prostate cancer in the next 24 months? ESO Observatory: Perspective on endocrine and chemotherapy agents
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr.Sternberg has received research funding for
More informationOptimizing Outcomes in Advanced Prostate Cancer
Optimizing Outcomes in Advanced Prostate Cancer Module 3: Focus on Recent CRPC Guidelines and Advanced Hormone-Sensitive Disease Sébastien J. Hotte, MD, MSc (HRM), FRCPC Medical Oncologist and Head, Phase
More informationThe management and treatment options for secondary bone disease. Omi Parikh July 2013
The management and treatment options for secondary bone disease Omi Parikh July 2013 Learning Objectives: The assessment and diagnostic process of patients with suspected bone metastases e.g bone scan,
More informationThe management and treatment options for secondary bone disease. Dr Jason Lester Clinical Oncologist Velindre Cancer Centre
The management and treatment options for secondary bone disease Dr Jason Lester Clinical Oncologist Velindre Cancer Centre Aims Overview of bone metastases management in castrate-refractory prostate cancer
More informationÁLVARO PINTO. Servicio de Oncología Médica Hospital Universitario La Paz IdiPAZ, Madrid
ACTUALIZACIÓN EN EL ABORDAJE DEL CÁNCER DE PRÓSTATA METASTÁSICO HORMONO--SENSIBLE HORMONO ÁLVARO PINTO Servicio de Oncología Médica Hospital Universitario La Paz IdiPAZ, Madrid ADT + docetaxel: a new standard
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationManagement of Prostate Cancer
Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and
More informationAdvanced Prostate Cancer. Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options
Advanced Prostate Cancer Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options Disclaimer This slide deck in its original and unaltered format is for educational purposes and
More informationCURRENT STATUS AND POTENTIAL OF ALPHA-EMITTING RADIOPHARMACEUTICALS
CURRENT STATUS AND POTENTIAL OF ALPHA-EMITTING RADIOPHARMACEUTICALS Chaitanya Divgi, MD crdivgi@gmail.com NO DISCLOSURES Objectives Aware of the types of radionuclides with therapeutic potential. Familiar
More informationNovel treatment for castration-resistant prostate cancer
Novel treatment for castration-resistant prostate cancer Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Treatment options for patients
More informationRadiopharmaceuticals for treating CRPC patients with metastatic bone disease 2014/6/27
Radiopharmaceuticals for treating CRPC patients with metastatic bone disease 和信醫院黃玉儀 2014/6/27 Bone metastases in prostate cancer The most common site of metastasis in prostate cancer In >90% patients
More informationRipamonti C, et al. ASCO 2012 (Abstract 9005)
ZOOM: A Prospective, Randomized Trial of Zoledronic Acid for Long-term Treatment in Patients With Bone-Metastatic Breast Cancer After 1 Year of Standard Zoledronic Acid Treatment D. Amadori, M. Aglietta,
More informationBone Metastases. Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital
Bone Metastases Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital 1 Outline Pathophysiology Signs & Symptoms Diagnosis Treatment Spinal Cord Compression 2 General Information
More informationTherapeutic management of bone metastasis in prostate cancer: an update
Expert Review of Anticancer Therapy ISSN: 1473-7140 (Print) 1744-8328 (Online) Journal homepage: http://www.tandfonline.com/loi/iery20 Therapeutic management of bone metastasis in prostate cancer: an update
More informationStrategic decisions for systemic treatment. metastatic castration resistant prostate cancer (mcrpc)
Strategic decisions for systemic treatment metastatic castration resistant prostate cancer (mcrpc) SAMO Luzern 14.09.2012 Richard Cathomas Onkologie Kantonsspital Graubünden richard.cathomas@ksgr.ch mcrpc
More informationManaging Skeletal Metastases
School of Breast Oncology 2012 Managing Skeletal Metastases Cathy Van Poznak, MD Assistant Professor University of Michigan Comprehensive Cancer Center Saturday, November 3, 2012 Learning Objectives: Define
More informationQuando e qual o momento de iniciar os Bifosfonatos no Câncer de Próstata
Quando e qual o momento de iniciar os Bifosfonatos no Câncer de Próstata Igor A. Protzner Morbeck, MD, MSc Professor de Medicina Universidade Católica de Brasília Oncologista Clínico Onco-Vida Brasília-DF
More informationSequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC)
Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Amit Bahl Consultant Oncologist Bristol Cancer Institute Clinical Director Spire Specialist Care Centre UK Disclosures Advisory
More informationNuevas perspectivas en el cáncer de próstata hormono-sensible metastásico Tratamiento actual del cáncer de próstata. Situación de Enzalutamida
Nuevas perspectivas en el cáncer de próstata hormono-sensible metastásico Tratamiento actual del cáncer de próstata. Situación de Enzalutamida Dr Pablo Maroto Hospital Sant Pau Dr Pablo Maroto Hospital
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/28765 holds various files of this Leiden University dissertation. Author: Wissing, Michel Daniël Title: Improving therapy options for patients with metastatic
More informationSaad et al [12] Metastatic CRPC. Bhoopalam et al [14] M0 PCa on ADT <1 yr vs >1 yr ADT
Evolution of Treatment Options for Patients with and Bone Metastases Trials of Treatments for Castration-Resistant Prostrate Cancer Mentioned in This Review Bisphosphonates (Zometa) 4 mg IV 8 mg IV ( to
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Rhona McMenemin Consultant in Clinical Oncology The
More informationESMO SUMMIT AFRICA Practice changing studies in Prostate Cancer in 2016 and 2017 and cost-effectiveness Ronald de Wit
ESMO SUMMIT AFRICA 2018 Practice changing studies in Prostate Cancer in 2016 and 2017 and cost-effectiveness Ronald de Wit CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche Merck Lilly 14 years of
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 11 April 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 11 April 2012 XGEVA 120 mg, solution for injection 1 glass vial of 120 mg/1.7 ml (CIP code: 217 253-8) 4 glass vials
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More informationDr. Tia Higano University of Washington Seattle, USA
AN UPDATE ON THE TREATMENT OF PATIENTS WITH mcrpc WITH RA-223 PLUS AAP Dr. Tia Higano University of Washington Seattle, USA AAP, Abiraterone Acetate and Prednisone/Prednisolone; mcrpc, metastatic Castration-Resistant
More informationFocus sulla malattia metastatica ormonosensibile (mhspc) ADT e Terapia ormonale: quando e a chi?
Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Terapia ormonale: quando e a chi? Paolo Andrea Zucali Dipartimento di Oncologia HUMANITAS CANCER CENTER Rozzano - Milano AGENDA Literature
More informationHormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering
> Hormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific
More informationManaging Skeletal Metastases
Managing Skeletal Metastases Alison Stopeck, M.D. Professor of Medicine Director, Breast Cancer Program University of Arizona Cancer Center Tucson, AZ Disclosures: Consulting, research funding, and honoraria
More informationHormonal Manipulations in CRPC. NW Clarke Professor of Urological Oncology Manchester UK
Hormonal Manipulations in CRPC NW Clarke Professor of Urological Oncology Manchester UK Standard Treatment of CRPC Pre 2004 (and in 2013?) PSA progression 99m Tc BS negative CT scan large lymph node component
More informationNOVITÀ IN TEMA DI NEOPLASIA DELLA PROSTATA L ALGORITMO TERAPEUTICO NEL CARCINOMA DELLA PROSTATA METASTATICO SENSIBILE ALLA CASTRAZIONE
NOVITÀ IN TEMA DI NEOPLASIA DELLA PROSTATA L ALGORITMO TERAPEUTICO NEL CARCINOMA DELLA PROSTATA METASTATICO SENSIBILE ALLA CASTRAZIONE S.S. Oncologia Medica Genitourinaria Outline 1. Clinical case 2. Chemotherapy
More informationApproved SYNOPSIS. Product: Denosumab (AMG 162) Interim Synopsis Clinical Study Report: Date: 23 July 2010.
Page 2 of 24012 SYNOPSIS Name of Sponsor: Amgen Inc Name of Finished Product: not applicable Name of Active Ingredient: denosumab (AMG 162) Title of Study: A Randomized, Double-Blind, Multicenter Study
More information2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC
Ronald de Wit Erasmus MC Cancer Institute The Netherlands 2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC Disclosures Sanofi ; research grant support, consultancy and speaker fees Astellas;
More informationFrancesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Prostata: Oral Communications Emerging strategies and controversial topics in advanced prostate cancer Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationSecond line hormone therapies. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Second line hormone therapies Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers
More informationFarmaci bone-targeted: basi biologiche e razionale d uso. Giovanni Pavanato Rovigo
Farmaci bone-targeted: basi biologiche e razionale d uso Giovanni Pavanato Rovigo DICHIARAZIONE Relatore: Giovanni Pavanato Come da nuova regolamentazione della Commissione Nazionale per la Formazione
More informationSession 5: Isotope therapies and palliative radiotherapy
Session 5: Isotope therapies and palliative radiotherapy Jeffrey Tuan, FRCR Radiation Oncology National Cancer Centre Singapore 15 Dec 2016 Bone metastases SREs are clinically important endpoints The burden
More informationSIMPOSIO. Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico
SIMPOSIO Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico Definition of Oligometastatic PCa 1-3 synchronous metastases (bone and/or lymph nodes) 2-5 synchronous metastases
More informationFrancesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Chemioterapia: quando e a chi? Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
More informationRadium-223 in a Community Setting for Castration Resistant Prostate Cancer
Cancer and Clinical Oncology; Vol. 6, No. 1; 2017 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Radium-223 in a Community Setting for Castration Resistant Prostate
More informationINTERGRATING NON- HORMONAL THERAPIES INTO PROSTATE CANCER
INTERGRATING NON- HORMONAL THERAPIES INTO PROSTATE CANCER Daniel George, MD Professor of Medicine and Surgery Director of Genitourinary Oncology Program Duke Cancer Institute 1 Disclosures Consultant:
More informationSecondary Hormonal therapies in mcrpc
Secondary Hormonal therapies in mcrpc Ravindran Kanesvaran Consultant,Division of Medical Oncology National Cancer Centre Singapore 1 Disclosures Research Support/P.I. Sanofi Consultant Major Stockholder
More informationJoelle Hamilton, M.D.
Joelle Hamilton, M.D. www.urologycentersalabama.com Case Presentation: CRPC, Rising PSA 70 yo healthy, fit, active man post RALP 8 years prior with rising PSA Rising PSA from 0.02 nadir to 3.4 thus ADT
More informationDENOSUMAB. . Peter Harper Guy s, King s & St Thomas & Leaders in Oncology Care (LOC) DENOSUMAB. RANK-L/Bisphosphonates; Bone secondaries & Lung Cancer
DENOSUMAB. Peter Harper Guy s, King s & St Thomas & Leaders in Oncology Care (LOC) DENOSUMAB RANK-L/Bisphosphonates; Bone secondaries & Lung Cancer. Peter Harper Guy s, King s & St Thomas & Leaders in
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationChemohormonal Therapy For Prostate Cancer. What is old, is new again!
Chemohormonal Therapy For Prostate Cancer What is old, is new again! Mount Tremblant January 20, 2017 Kala S. Sridhar MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital Head, GU Medical Oncology
More informationNCCP Chemotherapy Regimen. Radium 223 Therapy
INDICATIONS FOR USE: Radium 223 Therapy INDICATION ICD10 Regimen Code *Reimbursement Status As monotherapy or in combination with LHRH analogues for the treatment of adults with progressive castration-resistant
More informationHOW I DO IT. Introduction. BARKIN J. How I Do It: Managing bone health in patients with prostate cancer. Can J Urol 2014;21(4):
HOW I DO IT How I Do It: Managing bone health in patients with prostate cancer Jack Barkin, MD Department of Surgery, University of Toronto, Humber River Hospital, Toronto, Ontario, Canada BARKIN J. How
More informationimproving outcomes and identifying predictors of survival in clinical practice
European Journal of Nuclear Medicine and Molecular Imaging (218) 45:2264 2273 https://doi.org/1.17/s259-18-483-3 ORIGINAL ARTICLE 223 Ra-Dichloride in castration-resistant metastatic prostate cancer: improving
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationPhilip Kantoff, MD Dana-Farber Cancer Institute
CHEMOTHERAPY FOR MCRPC Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School 1 Disclosure of Financial Relationships With Any Commercial Interest Name Nature of Financial Commercial Interests
More informationWinston Tan MD FACP Associate Professor of Medicine Mayo Clinic Florida
Winston Tan MD FACP Associate Professor of Medicine Mayo Clinic Florida } none } To develop an understanding of the management of bone metastasis through a multidisciplinary approach } Enable the learner
More informationA SPECIAL MEETING REVIEW EDITION. Special Reporting on: PLUS Meeting Abstract Summaries. With Expert Commentary by:
August 2013 Volume 11, Issue 8, Supplement 11 A SPECIAL MEETING REVIEW EDITION Highlights in Advanced Prostate Cancer From the 2013 American Urological Association Annual Meeting and the 2013 American
More informationNavigating Prostate Cancer Therapy. Nevin Murray MD Clinical Professor of Medicine, UBC Medical Oncologist, BCCA
Navigating Prostate Cancer Therapy Nevin Murray MD Clinical Professor of Medicine, UBC Medical Oncologist, BCCA Disclosures In compliance with accreditation, we require the following disclosures to the
More informationMetastatic castrate-resistant prostate cancer: Toward a chronic disease
Metastatic castrate-resistant prostate cancer: Toward a chronic disease Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France General recommendations in CRPC Check serum Testosterone (should
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationBone Metastases and Mortality: Can We Be Doing More?
Bone Metastases and Mortality: Can We Be Doing More? Leonard G. Gomella, MD Chairman, Department of Urology President Society of Urologic Oncology Sidney Kimmel Cancer Center Thomas Jefferson University
More informationPlease consider the following information on ZYTIGA (abiraterone acetate). ZYTIGA - Compendia Communication - NCCN LATITUDE and STAMPEDE June 2017
Page 1 of 2 Janssen Scientific Affairs, LLC 1125 Trenton-Harbourton Road PO Box 200 Titusville, NJ 08560 800.526.7736 tel 609.730.3138 fax June 08, 2017 Joan McClure 275 Commerce Drive #300 Fort Washington,
More informationBone Health in Patients with Multiple Myeloma
Bone Health in Patients with Multiple Myeloma Amrita Y. Krishnan, MD Director Judy and Bernard Briskin Myeloma Center City of Hope Comprehensive Cancer Center Bone Health Bisphosphonates in Space Bone
More informationRoutine monitoring requirements for your mcrpc patients on Xofigo
XOFIGO IS INDICATED for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Introduce Xofigo at the first sign
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Zoledronic acid Therapeutic Area of Trial Breast cancer, prostrate cancer Approved Indication Prevention of skeletal related events
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationDecision follows a recommendation from Independent Data Monitoring Committee (IDMC)
News Release Intended for U.S. Media Phase III trial of radium Ra 223 dichloride in combination with abiraterone acetate and prednisone/prednisolone for patients with metastatic castration-resistant prostate
More informationNew Treatment Options for Prostate Cancer
New Treatment Options for Prostate Cancer Moderator: Jeremy P. Goldberg, President, JPG Healthcare LLC Panelists: Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana- Farber Cancer
More information